Latest news with #NEI
Cision Canada
6 days ago
- Business
- Cision Canada
NEI announces change to its leadership team Français
TORONTO, July 23, 2025 /CNW/ - NEI Investments (NEI) today announced that Adelaide Chiu, VP, Head of Responsible Investing, departed the organization on July 14, 2025. Her responsibilities as portfolio manager of certain NEI funds have been assumed by John Bai, Chief Investment Officer, effective July 14, 2025. About NEI NEI Investments is part of the asset management arm of Aviso Wealth Inc. (Aviso), one of Canada's leading wealth services providers. NEI holds over $13 billion in assets under management as of June 30, 2025. NEI adopts a differentiated approach to achieving investment returns for Canadians, leveraging a unique structure that includes a global network of money managers, proprietary investment management and asset allocation and a dedicated responsible investing team. This structure is designed to optimally respond to the dynamics of a changing world, uncover unique investment opportunities, and deliver a broad array of investment outcomes with financial growth at the core. About Aviso Aviso is a leading wealth management services provider for the Canadian financial industry, with approximately $150 billion in total assets under administration and management as of June 30, 2025. We're building a technology-enabled, client-centric wealth management ecosystem. Our clients include our partners, advisors and investors. We're a trusted partner for nearly all credit unions across Canada, in addition to a wide range of portfolio managers, investment dealers, insurance and trust companies, and introducing brokers. Our partners depend on Aviso for specific solutions that give them a competitive edge in a rapidly evolving, highly competitive industry. Our dual-registered investment and mutual fund dealer and our insurance services support thousands of investment advisors. Our asset manager oversees a growing lineup of investment solutions, including NEI funds and portfolios. Our Managed Assets Program provides a comprehensive range of separately managed accounts. Our online brokerage, Qtrade Direct Investing®, empowers self-directed investors, and our fully automated investing service, Qtrade Guided Portfolios®, serves investors who prefer a hands-off approach. Aviso Correspondent Partners provides custodial and carrying broker services to a wide range of firms. Aviso is backed by the collective strength of our owners: the credit union Centrals, Desjardins, and Co-operators/CUMIS. We're proud to power businesses that empower investors. For more information visit Aviso is a wholly owned subsidiary of Aviso Wealth LP, which in turn is owned 50% by Desjardins Financial Holding Inc. and 50% by a limited partnership owned by the five provincial credit union Centrals and The CUMIS Group Limited. The following entities are subsidiaries of Aviso: Aviso Financial Inc. (including divisions Aviso Wealth, Qtrade Direct Investing, Qtrade Guided Portfolios, Aviso Correspondent Partners), Aviso Insurance Inc., Credential Insurance Services Inc. and Northwest & Ethical Investments L.P. NEI Investments is a registered trademark of Northwest & Ethical Investments L.P. (NEI LP). Northwest & Ethical Investments Inc. is the general partner of NEI LP and a wholly owned subsidiary of Aviso Wealth Inc. Online brokerage services are offered through Qtrade Direct Investing. Mutual funds and other securities are offered through Aviso Wealth. Qtrade Direct Investing, Qtrade Guided Portfolios, Aviso Correspondent Partners, and Aviso Wealth are divisions of Aviso Financial Inc. Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus and/or Fund Facts before investing. Mutual funds are not guaranteed, their values change frequently, and past performance may not be repeated.
Malaysian Reserve
13-06-2025
- Business
- Malaysian Reserve
Foundation CEO Provides Expert Testimony to U.S. Senate as Outside Witness on Vision Research Funding
Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status COLUMBIA, Md., June 13, 2025 /PRNewswire/ — The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, today submitted written testimony to the U.S. Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies through its chief executive officer, Jason Menzo, who served as an expert outside witness. In the testimony, Menzo urged the Subcommittee to deliver robust and sustained funding for the National Eye Institute (NEI) in Fiscal Year 2026 and to preserve NEI's status as an independent institute within the National Institutes of Health (NIH). 'NEI is the only federal institute dedicated exclusively to vision research,' said Jason Menzo, CEO of the Foundation Fighting Blindness. 'Its work is restoring sight, advancing precision medicine, and delivering hope to millions of Americans living with retinal diseases. Continued investment is critical to maintaining momentum and achieving breakthroughs for conditions that currently have no cure.' The Foundation's testimony highlights how NEI-supported research has led to transformative discoveries, including the first FDA-approved gene therapy for an inherited disease, and emphasizes NEI's strategic role in public-private collaborations that accelerate treatment development. The Foundation Fighting Blindness and NEI have long shared a close, collaborative partnership to advance high-impact scientific discovery and bring new treatments to patients faster. Vision loss from diseases such as retinitis pigmentosa, macular degeneration, and Stargardt disease currently affects tens of millions and costs the U.S. economy an estimated $134.2 billion annually. The Foundation emphasized that inconsistent funding stalls clinical trials, closes labs, and risks losing top scientific talent—consequences that are difficult and costly to reverse. The testimony also noted that for every dollar invested in NIH-funded research, $2.56 in new economic activity is generated, making this one of the highest-return investments Congress can make. 'We're not just talking about restoring sight—we're talking about protecting America's leadership in biomedical innovation and supporting economic growth in communities nationwide,' added Menzo. The Foundation Fighting Blindness urges Congress to: Provide strong, sustained funding for NEI in the FY2026 Labor-HHS Appropriations bill; and Preserve NEI's status as an independent institute within NIH to ensure focused, strategic investment in vision science. The full testimony is available at About the Foundation Fighting BlindnessEstablished in 1971, the Foundation Fighting Blindness is the world's leading private source of funding for research on retinal degenerative diseases. The Foundation has raised over $954 million toward its mission to prevent, treat, and cure blinding diseases such as retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and more. Visit for more information. Media Contacts:Chris AdamsVice President, Marketing & CommunicationsCAdams@ 423-0585
Yahoo
13-06-2025
- Business
- Yahoo
Foundation CEO Provides Expert Testimony to U.S. Senate as Outside Witness on Vision Research Funding
Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status COLUMBIA, Md., June 13, 2025 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, today submitted written testimony to the U.S. Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies through its chief executive officer, Jason Menzo, who served as an expert outside witness. In the testimony, Menzo urged the Subcommittee to deliver robust and sustained funding for the National Eye Institute (NEI) in Fiscal Year 2026 and to preserve NEI's status as an independent institute within the National Institutes of Health (NIH). "NEI is the only federal institute dedicated exclusively to vision research," said Jason Menzo, CEO of the Foundation Fighting Blindness. "Its work is restoring sight, advancing precision medicine, and delivering hope to millions of Americans living with retinal diseases. Continued investment is critical to maintaining momentum and achieving breakthroughs for conditions that currently have no cure." The Foundation's testimony highlights how NEI-supported research has led to transformative discoveries, including the first FDA-approved gene therapy for an inherited disease, and emphasizes NEI's strategic role in public-private collaborations that accelerate treatment development. The Foundation Fighting Blindness and NEI have long shared a close, collaborative partnership to advance high-impact scientific discovery and bring new treatments to patients faster. Vision loss from diseases such as retinitis pigmentosa, macular degeneration, and Stargardt disease currently affects tens of millions and costs the U.S. economy an estimated $134.2 billion annually. The Foundation emphasized that inconsistent funding stalls clinical trials, closes labs, and risks losing top scientific talent—consequences that are difficult and costly to reverse. The testimony also noted that for every dollar invested in NIH-funded research, $2.56 in new economic activity is generated, making this one of the highest-return investments Congress can make. "We're not just talking about restoring sight—we're talking about protecting America's leadership in biomedical innovation and supporting economic growth in communities nationwide," added Menzo. The Foundation Fighting Blindness urges Congress to: Provide strong, sustained funding for NEI in the FY2026 Labor-HHS Appropriations bill; and Preserve NEI's status as an independent institute within NIH to ensure focused, strategic investment in vision science. The full testimony is available at About the Foundation Fighting BlindnessEstablished in 1971, the Foundation Fighting Blindness is the world's leading private source of funding for research on retinal degenerative diseases. The Foundation has raised over $954 million toward its mission to prevent, treat, and cure blinding diseases such as retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and more. Visit for more information. Media Contacts:Chris AdamsVice President, Marketing & CommunicationsCAdams@ 423-0585 View original content to download multimedia: SOURCE Foundation Fighting Blindness
Yahoo
18-03-2025
- Business
- Yahoo
HydroGraph and NEI Corporation Announce New Line of Graphene Dispersions
Innovative dispersions leverage HydroGraph's high-purity graphene technology to enhance electrode conductivity TORONTO, March 18, 2025 (GLOBE NEWSWIRE) -- HydroGraph Clean Power Inc. (CSE: HG) (OTCQB: HGRAF) (FRA: M98) (the 'Company' or 'HydroGraph'), a sustainable commercial manufacturer of high-purity graphene, and NEI Corporation, a leader in battery materials and testing services, announced the launch of NANOMYTE® FGA-1AD and NANOMYTE® FGA-1ND, a new line of advanced graphene dispersions. These innovative dispersions, a result of the companies' strategic collaboration, integrate seamlessly into existing electrode slurries, replacing or supplementing traditional conductive carbons to enhance electrode performance. The outcome is improved electrical conductivity, enabling the development of better electrodes and expanding possibilities for high-performance energy storage solutions. The global graphene dispersion market is projected to reach $1.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 16.5%. As demand for high-performance energy storage increases, the new graphene dispersions are progressively critical for accelerating the development of renewable energy systems and electric vehicles. The advanced graphene dispersions have the potential to make batteries more efficient and reliable. HydroGraph is poised to support this rapidly growing demand through its collaboration with NEI Corporation. By leveraging HydroGraph's novel graphene technology and NEI's expertise in battery materials, the companies are creating a strong foundation for future innovations and market expansion in the energy storage space. 'Our collaboration with NEI Corporation has already resulted in our next-generation graphene materials being made available in a format familiar to the battery industry,' said Kjirstin Breure, CEO and President of HydroGraph. 'These new dispersions aren't just enabling customers to test and enhance battery performance, but they are also setting the stage for broader graphene adoption across the energy storage sector. I'm proud to say that this is just the beginning of what our partnership can accomplish.' The two new advanced dispersions combine HydroGraph's pristine fractal graphene technology with NEI's extensive experience in battery materials. The result is a ready-to-use concentrate of high-purity graphene additive exhibiting 100% sp2 bonded carbon, in a turbostratic arrangement, and an average of six graphene layers per particle. This nanoscale structure significantly enhances conductivity, improves rate capability, and increases energy density, delivering a major performance advantage across a range of battery applications. These novel graphene dispersions present a range of potential applications for advanced energy storage systems, which will enhance NEI's line of products. These possibilities include its use as a high-performance conductive additive in lithium-ion battery anodes, particularly those based on silicon or silicon oxide, and cathodes based on LFP, LMFP and NMCs. Supercapacitor electrodes could also benefit from the use of graphene dispersions. Product Specifications NANOMYTE® FGA-1AD FGA-1AD is a ready-to-use aqueous graphene dispersion designed to replace or supplement traditional conducting carbons in electrode slurries to enhance performance. Description: 7 wt.% Graphene dispersion in water Density (20 °C): 1.04 g/cc Viscosity (20 °C): 150 cP (40 s-1) Available Quantities: 1L and 4L (request quote) Technical Links: Specification Sheet (pdf) | Safety Data Sheet (pdf) NANOMYTE® FGA-1ND FGA-1ND is a ready-to-use NMP-based graphene dispersion designed to replace or supplement traditional conducting carbons in electrode slurries to enhance performance. Description: 7 wt.% Graphene dispersion in NMP (N-methyl-2-pyrrolidone) Density (20 °C): 1.07 g/cc Viscosity (20 °C): 1200 cP (40 s-1) Available Quantities: 200mL, 500mL, 1L, and 4L (request quote) Technical Links: Specification Sheet (pdf) | Safety Data Sheet (pdf) "Collaborative innovation drives progress in the battery industry,' says Ganesh Skandan, CEO of NEI Corporation. 'NEI 's partnership with Hydrograph, combining our processing expertise with their high-quality graphene, demonstrates the power of strategic collaborations to advance energy storage solutions." HydroGraph and NEI Corporation launched their strategic partnership in November 2024, with a shared mission to accelerate the development and commercialization of advanced graphene-enhanced battery materials. The companies anticipate continued collaboration on new solutions designed to meet the increasing demand for high-performance energy storage technologies. For more information about HydroGraph, visit About Hydrograph Clean Power Inc. HydroGraph Clean Power Inc is a leading producer of pristine graphene using an 'explosion synthesis' process, which allows for exceptional purity, low energy use and identical batches. The quality, performance and consistency of HydroGraph's graphene follows the Graphene Council's Verified Graphene Producer® standards, of which very few graphene producers are able to meet. For more information or to learn about the HydroGraph story, visit: For company updates, please follow HydroGraph on LinkedIn and X. Forward-Looking Statements This release contains certain 'forward looking statements' and certain 'forward-looking information' as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as 'may', 'will', 'expect', 'intend', 'estimate', 'upon' 'anticipate', 'believe', 'continue', 'plans' or similar terminology. Forward-looking statements and information include, but are not limited to: statements in respect of the Private Placement, the use of the net proceeds from the Private Placement, the timing and ability of the Company to close the Private Placement, if at all, the gross proceeds of the Private Placement, the timing and ability of the Company to obtain all necessary regulatory approvals, if at all, and the terms and jurisdictions of the Private Placement; the statements in regards to existing and future products of the Company; the Company's future personnel appointments; the Company's plans and strategies. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of HydroGraph to control or predict, that may cause HydroGraph's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including but not limited to: HydroGraph's ability to implement its business strategies; risks associated with general economic conditions; adverse industry events; stakeholder engagement; marketing and transportation costs; loss of markets; volatility of commodity prices; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; industry and government regulation; changes in legislation, income tax and regulatory matters; competition; currency and interest rate fluctuations; and other risks. HydroGraph does not undertake any obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements. About NEI Corporation For over 27 years, NEI Corporation has provided advanced material solutions to customers worldwide. NEI excels in designing, developing, and producing application-specific materials. The company offers a comprehensive range of solutions, including cathode, anode, and electrolyte materials for lithium-ion and sodium-ion batteries, as well as extensive in-house materials development, characterization, and testing services. NEI's materials science expertise facilitates close partnerships and seamless product integration. CONTACTS HydroGraph Investor RelationsMatt Kreps, Darrow Associates IRmkreps@ Kjirstin Breure, HydroGraph President and HydroGraph Media ContactRaven Carpenterhydrograph@
